PR001833 (Project)

Id Namespace:

UCSD Metabolomics Workbench

Identifier Namespace (Entity type)

Dcc Asset:

MW submission packet 20250922.zip

Processed File (Entity type)

Dcc:

Metabolomics

DCC (Entity type)

Persistent Id:http://dx.doi.org/10.21228/M8SB0G

Description:Severe asthmatic patients prescribed either Mepolizumab or Omalizumab were followed during treatment, and serum samples were collected before treatment (T0), and both at 6 (T1) and 18 months (T2) after starting biological treatment. Treatment monitoring was performed by the analysis of a set of inflammatory metabolites using targeted metabolomics.

Results found

Linked to

	Label	Description
	PPR00001 Project (Entity type)	Metabolomics
	SU003061 Subject (Entity type)	A subject from Metabolomics produced as part of the PR001833 project
	SA321058 Biosample (Entity type)	A biosample from Metabolomics produced as part of the PR001833 project
	SA320919 Biosample (Entity type)	A biosample from Metabolomics produced as part of the PR001833 project
	SA320980 Biosample (Entity type)	A biosample from Metabolomics produced as part of the PR001833 project
	SA321036 Biosample (Entity type)	A biosample from Metabolomics produced as part of the PR001833 project
	SA321011 Biosample (Entity type)	A biosample from Metabolomics produced as part of the PR001833 project
	SA321038 Biosample (Entity type)	A biosample from Metabolomics produced as part of the PR001833 project
	SA320973 Biosample (Entity type)	A biosample from Metabolomics produced as part of the PR001833 project
	SA321061 Biosample (Entity type)	A biosample from Metabolomics produced as part of the PR001833 project

PPR00001

Project (Entity type)

Metabolomics

SU003061

Subject (Entity type)

A subject from Metabolomics produced as part of the PR001833 project

SA321058

Biosample (Entity type)